Significance of angiotensin II receptor blockers with high affinity to angiotensin II type 1 receptors for vascular protection in rats

Hypertension Research

Volumn 32, Issue 10, 2009, Pages 853-860

  Takai, Shinji ^a   Jin, Denan ^a   Ikeda, Hironobu ^b   Sakonjo, Hiroshi ^b   Miyazaki, Mizuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b Nissei BILIS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; ACETYLCHOLINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; OLMESARTAN; PLACEBO; PROTEIN P22; RENIN; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BINDING AFFINITY; BLOOD PRESSURE REGULATION; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; HEART WEIGHT; HYPERTENSION; IMMUNOHISTOLOGY; LIFE EXTENSION; MALE; NONHUMAN; PLASMA RENIN ACTIVITY; PROTECTION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SALT INTAKE; SALT LOADING; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT; SURVIVAL RATE; VASCULAR DISEASE; VASCULAR PROTECTION; VASODILATATION;

ACETYLCHOLINE; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CAROTID ARTERIES; HYPERTENSION; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; MALE; MUSCLE RELAXATION; NADPH OXIDASE; PEPTIDYL-DIPEPTIDASE A; PROTECTIVE AGENTS; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SODIUM-HYDROGEN ANTIPORTER; TETRAZOLES; VALINE; VASCULAR DISEASES;

EID: 70349984007     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.116     Document Type: Article

References (22)

1. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52: 11-34.
2. Pilote L, Abrahamowicz M, Rodrigues E, Eisenberg MJ, Rahme E. Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: A class effect? Ann Intern Med 2004; 141: 102-112.
3. Takai S, Sakonjo H, Miyazaki M. Beneficial effect of trandolapril on the lifespan of a severe hypertensive model. Hypertens Res 2001; 24 559-564.
4. Wienen W, Entzeroth M, Van Meel JCA, Stangier J, Busch U, Ebner T, Schmid J, Lehmann H, Matzek K, Kempthorne-Rawson J, Gladigau V, Hauel HH. A review on telmisartan: A novel, long-acting angiotensin II receptor antagonist. Cardiovasc Drug Rev 2000; 18: 127-156.
5. 1 receptor. Br J Pharmacol 2007; 151: 952-962.
6. Miura S, Kiya Y, Kanazawa T, Imaizumi S, Fujino M, Matsuo Y, Karnik SS, Saku K. Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol Endocrinol 2008; 22: 139-146.
7. Takai S, Jin D, Kimura M, Kirimura K, Sakonjo H, Tanaka K, Miyazaki M. Inhibition of vascular angiotensin-converting enzyme by telmisartan via the peroxisome proliferator-activated receptor γ agonistic property in rats. Hypertens Res 2007; 30: 1231-1237.
8. Takai S, Kirimura K, Jin D, Muramatsu M, Yoshikawa K, Mino Y, Miyazaki M. Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling. Hypertens Res 2005; 28: 593-600.
9. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity: Upstream mediators. Circ Res 2002; 91: 406-413.
10. phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 1997; 80: 45-51.
11. Hamilton CA, Brosnan MJ, Al-Benna S, Berg G, Dominiczak AF. NAD(P)H oxidase inhibition improves endothelial function in rat and human blood vessels. Hypertension 2002; 40: 755-762.
12. Jin D, Ueda H, Takai S, Okamoto Y, Muramatsu M, Sakaguchi M, Shibahara N, Katsuoka Y, Miyazaki M. Effect of chymase inhibition on the arteriovenous fistula stenosis in dogs. J Am Soc Nephrol 2005; 16: 1024-1034.
13. Liu J, Yang F, Yang XP, Jankowski M, Pagano PJ. NAD(P)H oxidase mediates angiotensin II-induced vascular macrophage infiltration and medial hypertrophy. Arterioscler Thromb Vasc Biol 2003; 23: 776-782.
14. 1 receptor blocker olmesartan. Hypertension 2004; 43: 263-269.
15. Hashimoto Y, Kurosawa Y, Minami K, Fushimi K, Narita H. A novel angiotensin II-receptor antagonist, 606A, induces regression of cardiac hypertrophy, augments endothelium-dependent relaxation and improves renal function in stroke-prone spontaneously hypertensive rats. Jpn J Pharmacol 1998; 76: 185-192.
16. Kerr S, Brosnan MJ, McIntyre M, Reid JL, Dominiczak AF, Hamilton CA. Superoxide anion production is increased in a model of genetic hypertension: Role of the endothelium. Hypertension 1999; 33 1353-1358.
17. Brosnan MJ, Hamilton CA, Graham D, Lygate CA, Jardine E, Dominiczak AF. Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats. J Hypertens 2002; 20: 281-286.
18. Yao EH, Fukuda N, Matsumoto T, Kobayashi N, Katakawa M, Yamamoto C, Tsunemi A, Suzuki R, Ueno T, Matsumoto K. Losartan improves the impaired function of endothelial progenitor cells in hypertension via an antioxidant effect. Hypertens Res 2007; 30: 1119-1128.
19. Pu Q, Brassard P, Javeshghani DM, Iglarz M, Webb RL, Amiri F, Schiffrin EL. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP. J Hypertens 2008; 26: 322-333.
20. Takai S, Jin D, Sakaguchi M, Muramatsu M, Miyazaki M. The regressive effect of an angiotensin II receptor blocker on formed fatty streaks in monkeys fed a high-cholesterol diet. J Hypertens 2005; 23: 1879-1886.
21. Agata J, Ura N, Yoshida H, Shinshi Y, Sasaki H, Hyakkoku M, Taniguchi S, Shimamoto K. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertens Res 2006; 29: 865-874.
22. Tom B, de Vries R, Saxena PR, Danser AH. Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N-domain blockade. Hypertension 2001; 38: 95-99.